<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00910598</url>
  </required_header>
  <id_info>
    <org_study_id>OCT</org_study_id>
    <nct_id>NCT00910598</nct_id>
  </id_info>
  <brief_title>Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS)</brief_title>
  <acronym>OCTIMS</acronym>
  <official_title>A Multicenter Longitudinal Cross-sectional Pilot Study, to Compare RNFL Thickness Measured by OCT After Treatment With Glatiramer or After no Treatment in Patients With CIS With or Without Optic Neuritis or With Early RRMS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amphia Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>TEVA Pharmachemie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Amphia Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study in patients with clinically isolated syndrome (CIS) and early relapsing&#xD;
      remitting multiple sclerosis (RRMS) to assess the effects of glatiramer acetate (GA)&#xD;
      subcutaneously on the condition of the optical nerve in comparison to no medicinal therapy&#xD;
      during 12 months and to assess the use of Optical Coherence tomography (OCT), a non-invasive&#xD;
      ophthalmological technique, in daily practice as an alternative to magnetic resonance imaging&#xD;
      (MRI) scanning for follow-up of these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple sclerosis (MS) is a progressive and demyelinating disease of the central nervous&#xD;
      system characterized by inflammation and neurodegeneration. It is characterized by an ongoing&#xD;
      process of demyelination and axonal loss, even at the beginning of the disease course, which&#xD;
      will result in brain atrophy. A first manifestation of clinical definite MS, is called a&#xD;
      clinically isolated syndrome (CIS). Brain atrophy occurs even in patients with a CIS. Optic&#xD;
      neuritis (ON) is a common feature of a CIS. The axons in the retina represent the most&#xD;
      proximal part of the optic nerve which is devoid of myelin. Because the retina is part of the&#xD;
      central nervous system (CNS), measurement of the Retinal Nerve Fiber Layer (RFLN) by Optical&#xD;
      Coherence Tomography (OCT) offers the opportunity to visualize the unmyelinated axons of the&#xD;
      CNS directly. OCT is a non-invasive method to measure the thickness of the optical layer. The&#xD;
      thickness of the RNFL is reduced in MS patients with or without ON history.&#xD;
&#xD;
      Glatiramer acetate (GA), an immunomodulatory drug for RRMS and CIS, reduces brain atrophy and&#xD;
      stimulates the production of brain-derived neurotrophic factor, which in turn could stimulate&#xD;
      neuroregeneration.&#xD;
&#xD;
      In this pilot study we would like to assess the feasibility of OCT measurement in patient&#xD;
      with CIS other than ON in the Dutch clinical setting and to assess the effect of GA on the&#xD;
      RNFL and visual function in patients with CIS or in early relapsing remitting MS patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">June 2012</completion_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of OCT measurement in patient with CIS with or without optic neuritis or with early RRMS in the Dutch clinical setting</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in RNFL in both eyes determined by OCT at baseline, month 3, month 6, month 9, month 12</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other ophthalmological parameters</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>glatiramer acetate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>glatiramer acetate 20 mg s.c. daily for 1 year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No disease modifying treatment allowed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glatiramer acetate</intervention_name>
    <description>20 mg daily s.c. for 1 year</description>
    <arm_group_label>glatiramer acetate</arm_group_label>
    <other_name>Copaxone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 18 - 55 years&#xD;
&#xD;
          -  Early relapsing remitting MS, defined as a disease course less than 3 years&#xD;
&#xD;
          -  clinically isolated syndrome , defined as optic neuritis (ON) or other than ON&#xD;
&#xD;
          -  Currently treated with glatiramer (GA) or currently not treated for MS&#xD;
&#xD;
          -  Expanded disability status scale (EDSS) score 0-5&#xD;
&#xD;
          -  Able and willing to provide written informed consent prior to enrolment&#xD;
&#xD;
          -  Willing and able to comply with the protocol requirements for the duration of the&#xD;
             study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical definite multiple sclerosis with a disease course more than 3 years&#xD;
&#xD;
          -  Primary progressive multiple sclerosis&#xD;
&#xD;
          -  Secondary progressive multiple sclerosis&#xD;
&#xD;
          -  Current use of any approved or investigational disease modifying agents for the&#xD;
             treatment of MS other than GA.&#xD;
&#xD;
          -  Neuromyelitis Optica (Devic's disease)&#xD;
&#xD;
          -  Any condition that may interfere with the quality of the OCT scan: clouding of the&#xD;
             media, i.e. cataract, pupil which are hard to dilate.&#xD;
&#xD;
          -  Contra-indications for Copaxone Â® as defined in the Summary of Product Characteristics&#xD;
             (SPC) text&#xD;
&#xD;
          -  Hypersensitivity to GA or mannitol&#xD;
&#xD;
          -  Subject's inability to complete the study or if the subject is considered by the&#xD;
             investigator to be for any reason, an unsuitable candidate for this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E.C.A.M. Sanders, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Amphia ziekenhuis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>E.C.A.M. Sanders, MD</last_name>
    <phone>+31 76 5258246</phone>
    <email>rsc@rsconsultancy.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raymond J. Schmidt, MD</last_name>
    <phone>+31 575 441001</phone>
    <email>rsc@rsconsultancy.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Amphia Ziekenhuis</name>
      <address>
        <city>Breda</city>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>E.C.A.M. Sanders, MD</last_name>
      <phone>+31 76 5258246</phone>
    </contact>
    <investigator>
      <last_name>E.C.A.M. Sanders, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maasland Ziekenhuis</name>
      <address>
        <city>Sittard</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R.M.M. Hupperts, MD PhD</last_name>
      <phone>+31 88 4597811</phone>
    </contact>
    <investigator>
      <last_name>R.M.M. Hupperts, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>S.A.M. Knippenberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.amphia.nl</url>
    <description>Amphia Hospital Breda Netherlands</description>
  </link>
  <verification_date>February 2010</verification_date>
  <study_first_submitted>May 29, 2009</study_first_submitted>
  <study_first_submitted_qc>May 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2009</study_first_posted>
  <last_update_submitted>February 9, 2010</last_update_submitted>
  <last_update_submitted_qc>February 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>E.C.A.M. Sanders</name_title>
    <organization>Amphia Ziekenhuis</organization>
  </responsible_party>
  <keyword>clinically isolated syndrome</keyword>
  <keyword>relapsing remitting multiple sclerosis</keyword>
  <keyword>glatiramer acetate</keyword>
  <keyword>Optical Coherence Tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glatiramer Acetate</mesh_term>
    <mesh_term>(T,G)-A-L</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

